Theralase Technologies Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line

Theralase Technologies (CVE:TLT) Second Quarter 2025 Results

Key Financial Results

• Revenue: CA$219.7k (up 118% from 2Q 2024).
• Net loss: CA$952.0k (loss narrowed by 16% from 2Q 2024).
• CA$0.004 loss per share (improved from CA$0.005 loss in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Theralase Technologies Earnings Insights

Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in North America.

Performance of the market in Canada.

The company's shares are down 2.3% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Theralase Technologies has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.